A study for a 20 year old woman who takes Onfi - from FDA reports


Summary

263 females aged 20 (±5) who take the same drug are studied. This is a personalized study for a 20 year old female patient who has Epilepsy. The study is created by eHealthMe based on reports from FDA.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA since 1977. Our tools are simple to use, anonymous and free. Start now >>>


On Aug, 03, 2017

263 females aged 20 (±5) who take Onfi are studied.


Number of reports submitted per year:

Onfi for a 20-year old woman.

Information of the patient in this study:

  • Age: 20
  • Gender: female
  • Conditions: Epilepsy
  • Drugs taken:
    • Onfi (clobazam)

eHealthMe real world results:

Most common side effects over time

< 1 month:
  • hallucination, visual
  • depersonalisation
  • memory loss
  • sensory disturbance
  • status epilepticus
  • drowsiness
  • eyelid twitch
  • nausea and vomiting
  • headache
  • umbilical cord around neck
1 - 6 months:
  • hepatic failure
  • hepatic steatosis
  • irritability
  • hepatitis toxic
  • diarrhea
  • drug ineffective
  • headache
  • liver transplant
  • haemoglobin decreased
  • aggression
6 - 12 months:
n/a
1 - 2 years:
  • head banging
  • aggression
  • rashes
  • anger
  • blood prolactin decreased
  • urticaria
  • intentional self-injury
2 - 5 years:
n/a
5 - 10 years:
  • chronic hepatitis
  • calculus bladder
  • aggression
  • agitation
10+ years:
n/a
not specified:
  • convulsion
  • drug ineffective
  • drowsiness
  • memory loss
  • fever
  • rashes
  • fatigue
  • status epilepticus
  • urinary tract infection
  • birth control

Top conditions involved for these people *:

  • Convulsion (16 people, 6.08%)
  • Lennox-Gastaut Syndrome (13 people, 4.94%)
  • Complex Partial Seizures (13 people, 4.94%)
  • Depression (10 people, 3.80%)
  • Angiomyolipoma (9 people, 3.42%)

Top co-used drugs for these people *:

  • Keppra (59 people, 22.43%)
  • Lamictal (40 people, 15.21%)
  • Lamotrigine (37 people, 14.07%)
  • Topiramate (36 people, 13.69%)
  • Vimpat (34 people, 12.93%)

* Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Subscribe to the study: get notified of updates to the study.

You can also:

Expand the study to include reports from both FDA and eHealthMe

Expand this study to include FDA and eHealthMe reports

What are the drugs?

What are the conditions?

Related studies:

Can you answer these questions?

More questions for: Onfi, Epilepsy

You may be interested in these reviews

More reviews for: Onfi, Epilepsy